Why Indivior’s Delaware redomiciliation matters more than a corporate address change
Find out how Indivior’s move to the United States reshapes governance, regulation, and investor perception in addiction treatment biotech.
Standard Process launches Cultivate symposium to advance whole-food nutrition strategies for healthy aging practitioners
Discover why Standard Process’ Cultivate symposium aims to close clinical education gaps in whole-food nutrition and reshape healthy aging care for practitioners.
Is bilateral delivery becoming the new standard in retinal gene therapy?
GenSight Biologics S.A.’s GS010/LUMEVOQ rollout in France and Israel has done more than expand access—it may be redefining how gene therapies are delivered in ophthalmology. As the company prepares for bilateral administration under early access programs for Leber Hereditary Optic Neuropathy (LHON), it is stepping into a growing shift across the field: a move away […]
From orthopedic cement to smart scaffolds: Is the next generation of bone adhesives finally viable in human use?
The recent U.S. Food and Drug Administration (FDA) approval for RevBio Inc. to begin a pilot trial of its regenerative bone adhesive, TETRANITE, in dental ridge augmentation has reignited industry attention around a long-elusive biomaterials category: viable, clinically integrated bone adhesives. While dental applications are the entry point, the real strategic question is whether these […]
Can early access programs reshape the approval arc for rare disease gene therapies?
GenSight Biologics S.A.’s early access rollout of GS010/LUMEVOQ in France and Israel has drawn new attention to how regulators are quietly repurposing compassionate use frameworks into strategic regulatory sandboxes for advanced therapies. As rare disease gene therapies edge closer to commercial viability, a patchwork of early access programs across key jurisdictions is beginning to influence […]
Is dental bone glue the new frontier in graft-free implantology? What RevBio’s TETRANITE trial could mean for chairside workflows
RevBio Inc. has received approval from the United States Food and Drug Administration to initiate a pilot clinical trial evaluating TETRANITE, its regenerative bone adhesive, for dental ridge augmentation procedures. The trial will examine whether the product can eliminate the need for membranes, meshes, tacks, and fixation screws—elements that have traditionally been considered essential for […]
How Sanofi’s CpG 1018 platform could reshape vaccine formulation in 2026
Sanofi’s acquisition of CpG 1018 brings TLR9 adjuvants to the forefront. Explore how this could transform combo vaccines and adult immunization strategies.
Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies
The recent FDA approval of Rubraca (rucaparib) for pre-chemotherapy use in BRCA-mutated metastatic castration-resistant prostate cancer marks a strategic inflection for the field. This expanded indication, driven by head-to-head superiority over docetaxel in the TRITON3 Phase 3 trial, positions BRCA mutations as the first molecular biomarker in prostate cancer to carry actionable, label-defining weight in […]
What is the regulome, and why is it becoming biotech’s new battleground?
Discover how biotech startups are targeting the regulome—the cell’s regulatory code—to unlock new drug targets beyond the genome and proteome.
Beyond biologics: Can structure-guided small molecules replace antibodies in intracellular targets?
For much of the past two decades, monoclonal antibodies have dominated modern drug development. Their ability to bind with high specificity, block protein function, and engage immune mechanisms has transformed the treatment of cancer, autoimmune disorders, and infectious disease. But despite their blockbuster status, biologics have a blind spot. They are largely excluded from the […]